Plain-English translation of NCT07277764 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new way to treat nasopharyngeal cancer (a type of throat cancer) that has come back after previous treatment. The study combines radiation therapy with an immune-boosting medication called anti-PD-1 monoclonal antibody, which helps your body's immune system fight cancer cells. The treatment is given in phases over several months, with the goal of shrinking the cancer and improving survival.
Nasopharyngeal cancer that returns after initial treatment is very difficult to treat, especially when surgery is not an option. This trial exists to see whether combining radiation with this medication can work better than radiation alone, by allowing your immune system to help destroy cancer cells alongside the radiation.
You likely qualify if…
You likely don't qualify if…
Over about 5–6 months, you would receive three initial doses of radiation therapy combined with two doses of the medication. After a break of 3–4 weeks, you would then receive daily radiation therapy (5 days per week) for about 5.5 weeks without the medication running at the same time. Finally, you would receive the medication alone every 3 weeks for up to 12 months to help maintain the response. Throughout the trial, you would have regular visits to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China